Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Gorovets

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Brachytherapy|June 20, 2022
Combined brachytherapy and ultra-hypofractionated radiotherapy for intermediate-risk prostate cancer: Comparison of toxicity outcomes using a high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy boostMarisa A Kollmeier, Daniel Gorovets, Jessica Flynn, et al.
The Prostate|March 22, 2023
Proton therapy for high-risk prostate cancer: Results from the Proton Collaborative Group PCG 001-09 prospective registry trialShaakir Hasan, Stanislav Lazarev, Madhur Garg, et al.
The Journal of Sexual Medicine|April 14, 2023
Sildenafil Citrate and Risk of Biochemical Recurrence in Prostate Cancer Patients Treated with Radiation Therapy: Post-Hoc Analysis of a Randomized Controlled TrialJustin M Haseltine, Margaret Hopkins, Elizabeth Schofield, et al.
International Journal of Radiation Oncology, Biology, Physics|January 10, 2017
Multi-institutional Nomogram Predicting Survival Free From Salvage Whole Brain Radiation After Radiosurgery in Patients With Brain MetastasesDaniel Gorovets, Diandra Ayala-Peacock, David J Tybor, et al.
European Urology Oncology|November 1, 2019
Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate CancerMichael J Zelefsky, Attapol Pinitpatcharalert, Marisa Kollmeier, et al.
Oncotarget|October 30, 2012
Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade gliomaKasthuri Kannan, Akiko Inagaki, Joachim Silber, et al.
Brachytherapy|September 30, 2021
Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancerDaniel Gorovets, Margaret Hopkins, Marisa Kollmeier, et al.
The American Journal of Hospice & Palliative Care|March 28, 2018
Early Palliative Care for Patients With Brain Metastases Decreases Inpatient Admissions and Need for Imaging StudiesAkram Habibi, S Peter Wu, Daniel Gorovets, et al.
European Urology Oncology|November 10, 2023
Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate CancerAssaf Moore, Marisa A Kollmeier, Sean M McBride, et al.
Clinical and Translational Radiation Oncology|December 11, 2020
Optimal timing of radiotherapy in high risk prostate cancer: Do missed days matter?Shaakir Hasan, Daniel Gorovets, Eric Lehrer, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Brachytherapy|June 20, 2022
Combined brachytherapy and ultra-hypofractionated radiotherapy for intermediate-risk prostate cancer: Comparison of toxicity outcomes using a high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy boostMarisa A Kollmeier, Daniel Gorovets, Jessica Flynn, et al.
The Prostate|March 22, 2023
Proton therapy for high-risk prostate cancer: Results from the Proton Collaborative Group PCG 001-09 prospective registry trialShaakir Hasan, Stanislav Lazarev, Madhur Garg, et al.
The Journal of Sexual Medicine|April 14, 2023
Sildenafil Citrate and Risk of Biochemical Recurrence in Prostate Cancer Patients Treated with Radiation Therapy: Post-Hoc Analysis of a Randomized Controlled TrialJustin M Haseltine, Margaret Hopkins, Elizabeth Schofield, et al.
International Journal of Radiation Oncology, Biology, Physics|January 10, 2017
Multi-institutional Nomogram Predicting Survival Free From Salvage Whole Brain Radiation After Radiosurgery in Patients With Brain MetastasesDaniel Gorovets, Diandra Ayala-Peacock, David J Tybor, et al.
European Urology Oncology|November 1, 2019
Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate CancerMichael J Zelefsky, Attapol Pinitpatcharalert, Marisa Kollmeier, et al.
Oncotarget|October 30, 2012
Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade gliomaKasthuri Kannan, Akiko Inagaki, Joachim Silber, et al.
Brachytherapy|September 30, 2021
Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancerDaniel Gorovets, Margaret Hopkins, Marisa Kollmeier, et al.
The American Journal of Hospice & Palliative Care|March 28, 2018
Early Palliative Care for Patients With Brain Metastases Decreases Inpatient Admissions and Need for Imaging StudiesAkram Habibi, S Peter Wu, Daniel Gorovets, et al.
European Urology Oncology|November 10, 2023
Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate CancerAssaf Moore, Marisa A Kollmeier, Sean M McBride, et al.
Clinical and Translational Radiation Oncology|December 11, 2020
Optimal timing of radiotherapy in high risk prostate cancer: Do missed days matter?Shaakir Hasan, Daniel Gorovets, Eric Lehrer, et al.
Pageof 5